Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Therna Therapeutics operates in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action in its patent portfolio. This action is being handled within 1 distinct art unit, which points to a specific focus on a particular technical niche. The presence of a single pending action suggests a targeted approach to its current intellectual property development within the Biotechnology & Pharmaceuticals sector.
The prosecution for the company involves 1 distinct examiner. PIPIC, ALMA is the busiest examiner for the portfolio, currently managing 1 pending office action. This count is identical to the total number of pending actions for the entire company. For a practitioner, this means that the company's current interaction with the patent office is entirely concentrated under one examiner's review. This concentration allows for a focused prosecution strategy tailored to the specific requirements of this examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PIPIC, ALMA | 1 | 54.8% | +54.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18571238 | LIPID NANOPARTICLES AND METHOD FOR PREPARING SAME | PIPIC, ALMA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18571238 | LIPID NANOPARTICLES AND METHOD FOR PREPARING SAME | PIPIC, ALMA | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18571238 | LIPID NANOPARTICLES AND METHOD FOR PREPARING SAME | PIPIC, ALMA | 1617 | §103§112 | Non-Final OA | — | Pending | Dec 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTherna Therapeutics has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alma Pipic has the most, with 1 of Therna Therapeutics's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
